We are an emerging biotechnology company dedicated to the discovery of small-molecule therapeutics and diagnostics for the treatment of the debilitating neurological orphan indication of amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease). We incorporate modern aspects of drug discovery including compound library synthesis and screening. In partnership with top academic and industrial laboratories, ALS Biopharma, LLC is researching both small molecule and biologic protein-based approaches to treat the disease.